 |
16 Diseases |  |
13 Trials |
|
13 Trials |  |
579 News |  |
| «1234567 |
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment open: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Feb 20, 2013
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting
- ||||| sotatercept (MK-7962) / BMS, Merck (MSD)
New P2 trial: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov) - Nov 27, 2012
P2, N=100, Recruiting, Sponsor: Celgene Corporation
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
New P2 trial: Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) - Oct 21, 2012
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Trial termination, Metastases: To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 27, 2012
P2a, N=25, Terminated, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting Recruiting --> Terminated; Persistent low enrollment made study continuation no longer feasible
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Enrollment change, Metastases: To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 27, 2012
P2a, N=25, Terminated, Sponsor: Celgene Corporation
Recruiting --> Terminated; Persistent low enrollment made study continuation no longer feasible N=90 --> 25
- | sotatercept (MK-7962) / BMS, Merck (MSD)
Enrollment change: A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis. (clinicaltrials.gov) - Apr 3, 2012
P2, N=43, Recruiting, Sponsor: Celgene Corporation
N=90 --> 25 N=32 --> 43
- ||||| sotatercept (MK-7962) / BMS, Merck (MSD)
New P2 trial: Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( ?)- Thalassemia. (clinicaltrials.gov) - Apr 3, 2012
P2, N=65, Recruiting, Sponsor: Celgene Corporation
- Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
Combination therapy: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 21, 2012
P1, N=34, Recruiting, Sponsor: Massachusetts General Hospital
- sotatercept (MK-7962) / BMS, Merck (MSD)
New P1/2 trial: Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia (clinicaltrials.gov) - Nov 1, 2011
P1/2, N=20, Recruiting, Sponsor: North Shore Long Island Jewish Health System